BSX - Boston Scientific Corp.
(NaN%)
SNP 500
Hold
Moderate Growth and Improving
58%
based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 15.65%
Operating Income turning Positive
Net Income Growth is 50.42%
Earnings Per Share (EPS) Growth is 47.56%
Net Margin is 11.27%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.48
Debt Ratio is 0.2
Current Debt to Net Income Ratio is 3.52
Total Debt to Total Assets Ratio is 0.29
Cash Flow is MODERATE
Cash from Operations Growth is 24.78%
Capital Expenditure is High
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Boston Scientific Corp. (BSX) - https://www.bostonscientific.com/
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Surgical and Medical Instrument Manufacturing
Sector - Manufacturing
CEO - Michael Mahoney
Employees - 45,000
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.
Know the Stock © 2024 and future.